Comparison of efficacy of SHENQI compound and rosiglitazone in the treatment of diabetic vasculopathy analyzing multi-factor mediated disease-causing modules.
Atherosclerosis-predominant vasculopathy is a common complication of diabetes with high morbidity and high mortality, which is ruining the patient's daily life. As is known to all, traditional Chinese medicine (TCM) SHENQI compound and western medicine rosiglitazone play an important role in th...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2018-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://doi.org/10.1371/journal.pone.0207683 |
| _version_ | 1819123636355727360 |
|---|---|
| author | Hong Gao Yuhong Duan Xiaoxu Fu Hongyan Xie Ya Liu Haipo Yuan Mingyang Zhou Chunguang Xie |
| author_facet | Hong Gao Yuhong Duan Xiaoxu Fu Hongyan Xie Ya Liu Haipo Yuan Mingyang Zhou Chunguang Xie |
| author_sort | Hong Gao |
| collection | DOAJ |
| description | Atherosclerosis-predominant vasculopathy is a common complication of diabetes with high morbidity and high mortality, which is ruining the patient's daily life. As is known to all, traditional Chinese medicine (TCM) SHENQI compound and western medicine rosiglitazone play an important role in the treatment of diabetes. In particular, SHENQI compound has a significant inhibitory effect on vascular lesions. Here, to explore and compare the therapeutic mechanism of SHENQI compound and rosiglitazone on diabetic vasculopathy, we first built 7 groups of mouse models. The behavioral, physiological and pathological morphological characteristics of these mice showed that SHENQI compound has a more comprehensive curative effect than rosiglitazone and has a stronger inhibitory effect on vascular lesions. While rosiglitazone has a more effective but no significant effect on hypoglycemic. Further, based on the gene expression of mice in each group, we performed differential expression analysis. The functional enrichment analysis of these differentially expressed genes (DEGs) revealed the potential pathogenesis and treatment mechanisms of diabetic angiopathy. In addition, we found that SHENQI compound mainly exerts comprehensive effects by regulating MCM8, IRF7, CDK7, NEDD4L by pivot regulator analysis, while rosiglitazone can rapidly lower blood glucose levels by targeting PSMD3, UBA52. Except that, we also identified some pivot TFs and ncRNAs for these potential disease-causing DEG modules, which may the mediators bridging drugs and modules. Finally, similar to pivot regulator analysis, we also identified the regulation of some drugs (e.g. bumetanide, disopyramide and glyburide etc.) which have been shown to have a certain effect on diabetes or diabetic angiopathy, proofing the scientific and objectivity of this study. Overall, this study not only provides an in-depth comparison of the efficacy of SHENQI compound and rosiglitazone in the treatment of diabetic vasculopathy, but also provides clinicians and drug designers with valuable theoretical guidance. |
| first_indexed | 2024-12-22T07:11:30Z |
| format | Article |
| id | doaj.art-0c6d6fe889d149bc81ced82e64adfdda |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-12-22T07:11:30Z |
| publishDate | 2018-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-0c6d6fe889d149bc81ced82e64adfdda2022-12-21T18:34:31ZengPublic Library of Science (PLoS)PLoS ONE1932-62032018-01-011312e020768310.1371/journal.pone.0207683Comparison of efficacy of SHENQI compound and rosiglitazone in the treatment of diabetic vasculopathy analyzing multi-factor mediated disease-causing modules.Hong GaoYuhong DuanXiaoxu FuHongyan XieYa LiuHaipo YuanMingyang ZhouChunguang XieAtherosclerosis-predominant vasculopathy is a common complication of diabetes with high morbidity and high mortality, which is ruining the patient's daily life. As is known to all, traditional Chinese medicine (TCM) SHENQI compound and western medicine rosiglitazone play an important role in the treatment of diabetes. In particular, SHENQI compound has a significant inhibitory effect on vascular lesions. Here, to explore and compare the therapeutic mechanism of SHENQI compound and rosiglitazone on diabetic vasculopathy, we first built 7 groups of mouse models. The behavioral, physiological and pathological morphological characteristics of these mice showed that SHENQI compound has a more comprehensive curative effect than rosiglitazone and has a stronger inhibitory effect on vascular lesions. While rosiglitazone has a more effective but no significant effect on hypoglycemic. Further, based on the gene expression of mice in each group, we performed differential expression analysis. The functional enrichment analysis of these differentially expressed genes (DEGs) revealed the potential pathogenesis and treatment mechanisms of diabetic angiopathy. In addition, we found that SHENQI compound mainly exerts comprehensive effects by regulating MCM8, IRF7, CDK7, NEDD4L by pivot regulator analysis, while rosiglitazone can rapidly lower blood glucose levels by targeting PSMD3, UBA52. Except that, we also identified some pivot TFs and ncRNAs for these potential disease-causing DEG modules, which may the mediators bridging drugs and modules. Finally, similar to pivot regulator analysis, we also identified the regulation of some drugs (e.g. bumetanide, disopyramide and glyburide etc.) which have been shown to have a certain effect on diabetes or diabetic angiopathy, proofing the scientific and objectivity of this study. Overall, this study not only provides an in-depth comparison of the efficacy of SHENQI compound and rosiglitazone in the treatment of diabetic vasculopathy, but also provides clinicians and drug designers with valuable theoretical guidance.https://doi.org/10.1371/journal.pone.0207683 |
| spellingShingle | Hong Gao Yuhong Duan Xiaoxu Fu Hongyan Xie Ya Liu Haipo Yuan Mingyang Zhou Chunguang Xie Comparison of efficacy of SHENQI compound and rosiglitazone in the treatment of diabetic vasculopathy analyzing multi-factor mediated disease-causing modules. PLoS ONE |
| title | Comparison of efficacy of SHENQI compound and rosiglitazone in the treatment of diabetic vasculopathy analyzing multi-factor mediated disease-causing modules. |
| title_full | Comparison of efficacy of SHENQI compound and rosiglitazone in the treatment of diabetic vasculopathy analyzing multi-factor mediated disease-causing modules. |
| title_fullStr | Comparison of efficacy of SHENQI compound and rosiglitazone in the treatment of diabetic vasculopathy analyzing multi-factor mediated disease-causing modules. |
| title_full_unstemmed | Comparison of efficacy of SHENQI compound and rosiglitazone in the treatment of diabetic vasculopathy analyzing multi-factor mediated disease-causing modules. |
| title_short | Comparison of efficacy of SHENQI compound and rosiglitazone in the treatment of diabetic vasculopathy analyzing multi-factor mediated disease-causing modules. |
| title_sort | comparison of efficacy of shenqi compound and rosiglitazone in the treatment of diabetic vasculopathy analyzing multi factor mediated disease causing modules |
| url | https://doi.org/10.1371/journal.pone.0207683 |
| work_keys_str_mv | AT honggao comparisonofefficacyofshenqicompoundandrosiglitazoneinthetreatmentofdiabeticvasculopathyanalyzingmultifactormediateddiseasecausingmodules AT yuhongduan comparisonofefficacyofshenqicompoundandrosiglitazoneinthetreatmentofdiabeticvasculopathyanalyzingmultifactormediateddiseasecausingmodules AT xiaoxufu comparisonofefficacyofshenqicompoundandrosiglitazoneinthetreatmentofdiabeticvasculopathyanalyzingmultifactormediateddiseasecausingmodules AT hongyanxie comparisonofefficacyofshenqicompoundandrosiglitazoneinthetreatmentofdiabeticvasculopathyanalyzingmultifactormediateddiseasecausingmodules AT yaliu comparisonofefficacyofshenqicompoundandrosiglitazoneinthetreatmentofdiabeticvasculopathyanalyzingmultifactormediateddiseasecausingmodules AT haipoyuan comparisonofefficacyofshenqicompoundandrosiglitazoneinthetreatmentofdiabeticvasculopathyanalyzingmultifactormediateddiseasecausingmodules AT mingyangzhou comparisonofefficacyofshenqicompoundandrosiglitazoneinthetreatmentofdiabeticvasculopathyanalyzingmultifactormediateddiseasecausingmodules AT chunguangxie comparisonofefficacyofshenqicompoundandrosiglitazoneinthetreatmentofdiabeticvasculopathyanalyzingmultifactormediateddiseasecausingmodules |